Can I Take N-Acetylcysteine (NAC) with Rezdiffra (Resmetirom)?

How Resmetirom Works in MASH

Resmetirom (brand name Rezdiffra) is a first-in-class oral thyroid hormone receptor beta (THR-beta) agonist. The FDA granted accelerated approval in March 2024 for adults with non-cirrhotic MASH and moderate-to-advanced hepatic fibrosis (stages F2 or F3). It works by selectively activating THR-beta in the liver, which increases hepatic fat metabolism, reduces lipotoxicity, and lowers circulating levels of atherogenic lipoproteins.

THR-Beta Selectivity and Liver Targeting

Unlike older thyroid hormone analogs, resmetirom binds THR-beta with roughly 28-fold selectivity over THR-alpha [1]. That selectivity matters. THR-alpha mediates most cardiac and bone effects of thyroid hormone, so bypassing it reduces the risk of tachycardia and bone loss. Resmetirom also undergoes high first-pass hepatic extraction, which concentrates drug exposure in the liver rather than systemic tissue [2].

The MAESTRO-NASH Trial

In the MAESTRO-NASH Phase 3 trial (N=966), 80 mg and 100 mg doses of resmetirom achieved MASH resolution without worsening fibrosis in 25.9% and 29.9% of patients, respectively, versus 9.7% for placebo at 52 weeks (P<0.001 for both) [3]. Fibrosis improvement by at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo. LDL cholesterol dropped by approximately 14 to 16% from baseline in the treatment arms.

Common Adverse Effects

The most frequently reported side effects in MAESTRO-NASH were diarrhea (27% vs. 17% placebo) and nausea (22% vs. 13% placebo). The FDA label requires monitoring of liver function tests because transaminase elevations were observed in a small subset of participants [4].

How NAC Works as a Glutathione Precursor

N-acetylcysteine is a synthetic derivative of the amino acid L-cysteine. It replenishes intracellular glutathione, the liver's primary endogenous antioxidant. The FDA approves NAC in two contexts: as a mucolytic (Mucomyst) and as the antidote for acetaminophen overdose. Over-the-counter NAC supplements are widely used at doses of 600 to 1,800 mg daily for general antioxidant support.

Glutathione and Hepatic Oxidative Stress

In MASH, oxidative stress drives hepatocyte injury and stellate cell activation, accelerating fibrosis. Glutathione depletion is measurable in liver biopsy samples from patients with steatohepatitis [5]. By supplying cysteine (the rate-limiting substrate for glutathione synthesis), NAC theoretically supports the liver's defense against reactive oxygen species. A 2023 meta-analysis of five randomized trials (N=349 total) in NAFLD patients found that NAC supplementation reduced ALT by a mean of 10.3 U/L compared with placebo, though the clinical significance of that reduction remains debated [6].

Limits of the Evidence

The Cochrane Hepato-Biliary Group published a 2021 systematic review concluding that evidence is insufficient to recommend NAC for non-acetaminophen acute liver failure [7]. For chronic liver conditions such as MASH, no large Phase 3 trial has tested NAC as a standalone therapy. Most positive signals come from small, short-duration studies. NAC is not a substitute for disease-modifying treatment.

Pharmacokinetic Interaction Analysis

The central question: does NAC alter how resmetirom is absorbed, distributed, metabolized, or eliminated? Based on currently available pharmacology data, the answer is no, through any well-characterized mechanism.

CYP450 Metabolism

Resmetirom undergoes hepatic metabolism primarily via CYP3A4, with a secondary contribution from CYP2C8 [4]. NAC does not function as a clinically meaningful inhibitor or inducer of CYP3A4, CYP2C8, or other major CYP isoforms at standard supplemental doses [8]. In vitro studies at supratherapeutic NAC concentrations have shown minimal impact on CYP enzyme activity. This contrasts sharply with true CYP3A4 inhibitors like ketoconazole or grapefruit juice, which can raise substrate drug exposure by 200 to 400%.

Transporter-Mediated Interactions

Resmetirom is a substrate of the organic anion transporting polypeptide OATP1B1, which mediates hepatic uptake [4]. NAC is not a recognized inhibitor of OATP1B1 or OATP1B3. No published case reports or pharmacovigilance signals suggest transporter-level interference between these two agents.

Absorption Considerations

NAC taken orally is rapidly absorbed with a bioavailability of roughly 6 to 10% due to extensive first-pass metabolism. Resmetirom should be taken with food to optimize absorption (the FDA label specifies administration with food) [4]. High-dose NAC (above 1,200 mg) can cause nausea and loose stools, which could theoretically reduce the time resmetirom spends in the absorptive window. For this reason, a two-hour separation between doses is a reasonable precaution, though no formal interaction study mandates it.

Pharmacodynamic Overlap: Complementary, Not Conflicting

Pharmacodynamic interactions occur when two drugs amplify or oppose each other's effects at the target level, even if blood concentrations remain unchanged.

Distinct Mechanisms on Liver Pathology

Resmetirom reduces hepatic steatosis by increasing mitochondrial fatty acid beta-oxidation through THR-beta activation. NAC works upstream of mitochondrial injury by restoring the glutathione pool that neutralizes lipid peroxides and reactive oxygen species. These pathways do not oppose each other. If anything, they are mechanistically complementary: resmetirom reduces the lipotoxic substrate burden while NAC buffers the oxidative damage that lipotoxicity generates.

Thyroid Function Considerations

NAC does not affect thyroid hormone levels or thyroid receptor signaling in published human data [9]. This is relevant because resmetirom's therapeutic window depends on selective THR-beta activation without systemic thyroid hormone excess. Supplements that alter iodine metabolism (such as kelp or high-dose selenium) carry more theoretical risk in this context than NAC does.

Additive Gastrointestinal Effects

Both agents can cause GI symptoms. Resmetirom produces diarrhea and nausea in a dose-dependent fashion. NAC at doses above 1,200 mg per day can trigger nausea, bloating, and loose stools [10]. Patients taking both should start NAC at the lower end of the dosing range (600 mg daily) and titrate upward only if GI tolerance allows. Separating the doses by two or more hours may reduce the additive GI burden.

Monitoring Recommendations When Combining NAC and Resmetirom

Even when no formal drug interaction exists, combining a prescription medication for advanced liver disease with an over-the-counter supplement warrants structured monitoring.

Liver Function Tests

The resmetirom FDA label recommends baseline hepatic function testing (ALT, AST, total bilirubin, alkaline phosphatase) before starting therapy, then periodic monitoring [4]. A reasonable schedule while co-administering NAC:

• Baseline labs before starting resmetirom
• Repeat at 4 weeks, 8 weeks, and 12 weeks
• Quarterly thereafter if values remain stable
• Recheck within two weeks if any dose change to either agent

ALT elevations above 5 times the upper limit of normal should prompt temporary discontinuation of resmetirom and reassessment. NAC can reduce ALT on its own, so paradoxically, modest ALT improvement might reflect NAC's antioxidant contribution rather than true histologic change.

Thyroid Panel

The FDA label notes that resmetirom can reduce TSH by approximately 20 to 30% through central feedback, while free T3 and free T4 typically remain within normal limits [4]. Check TSH, free T4, and free T3 at baseline, 8 weeks, and then every 6 months. NAC has no expected impact on these values, but documenting a stable thyroid panel after adding NAC is good practice.

Lipid Panel

Resmetirom significantly lowers LDL-C, apolipoprotein B, and triglycerides [3]. NAC has no established lipid-lowering effect. Track a lipid panel at baseline and 12 weeks to confirm that the expected lipid response is not blunted.

Dosing Strategy for the Combination

No regulatory body has issued formal guidance on co-administration timing. The following approach is based on pharmacokinetic first principles and clinical pragmatism.

Recommended Schedule

Take resmetirom with your morning meal, as directed by the FDA label. Take NAC at least two hours later (midday or evening) with food. This separation avoids any theoretical competition for GI absorption and reduces the chance of compounded nausea.

NAC Dose Range

For general antioxidant support in a MASH patient, 600 to 1,200 mg per day in divided doses is the range most commonly studied [6]. Doses above 1,800 mg per day have not been tested in combination with THR-beta agonists and are not recommended without physician oversight.

When to Stop NAC

Discontinue NAC and contact your prescriber if you experience unexplained jaundice, dark urine, severe abdominal pain, or ALT rising above 3 times the upper limit of normal on serial labs. These symptoms may indicate hepatotoxicity from resmetirom or disease progression, and an antioxidant supplement should not mask them.

Who Should Avoid This Combination

Most patients on resmetirom can take NAC without measurable pharmacologic risk. Specific populations warrant caution.

Patients with active peptic ulcer disease should avoid oral NAC, which can increase gastric acid secretion. Patients with a known allergy to acetylcysteine (anaphylactoid reactions have been reported during IV NAC administration for acetaminophen overdose) should not take any form of the supplement [10]. Patients on anticoagulants such as warfarin should note that very high-dose NAC (above 2,000 mg) has been associated with prolonged INR in isolated case reports, and resmetirom's effect on warfarin pharmacokinetics has not been extensively characterized [4].

Pregnant or breastfeeding patients should not take resmetirom (it is not studied in pregnancy), and the safety of NAC supplementation during pregnancy at doses above the mucolytic indication is not established.

What to Tell Your Prescriber

Bring the NAC bottle to your next appointment. Your hepatologist or prescribing clinician needs to know: the brand, dose, and frequency of your NAC supplement. Document when you started it relative to resmetirom initiation. If you were already taking NAC before starting Rezdiffra, your baseline liver enzymes may already reflect NAC's modest ALT-lowering effect, which influences how your clinician interprets subsequent labs.

Dr. Zobair Younossi, a hepatologist who chaired the AASLD Special Conference on NASH, has stated: "Patients with MASH often take multiple supplements. Clinicians need a complete supplement history to interpret liver chemistries accurately and to avoid attributing drug effects to disease progression or vice versa" [11].

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on NAFLD/MASH recommends that clinicians routinely ask about dietary supplements at every visit, given the prevalence of supplement use in this population [12].